| Relation |
Description |
Example |
| Expression |
Changes protein abundance by affecting levels of transcript or protein stability |
MDM2 has a negative "Expression" relationship with TP53 |
| miRNA Effect |
Inhibitory effect of an miRNA on its mRNA target |
miR-30 has a negative "miRNAEffect" relationship with TP53 |
| Promoter Binding |
Binds to the promoter of a gene |
FOXC1 has a positive "PromoterBinding" relationship with MMP7 |
| Regulation |
Changes activity by an unknown mechanism (may be direct or indirect) |
SOCS3 has a positive "Regulation" relationship with diabetes mellitus |
| Direct Regulation |
Influences activity by direct physical interaction |
BRCA1 has a "DirectRegulation" relationship with BARD1 |
| Binding |
Direct physical interaction between two molecules |
FANCD2 has a "Binding" relationship with BRCA1 |
| Protein Modification |
Changes the modification of the target molecule, usually by direct interaction |
SRC has a "ProtModification" relationship with GRB2 |
| Biomarker |
Identification of proteins/complexes/functional classes/metabolites that are prognostic or diagnostic biomarkers for a disease |
Lung cancer has a "Biomarker" relationship with IL6 |
| Genetic Change |
Genetic changes such as gene deletions, amplifications, mutations or epigenetic changes |
Lung cancer has a "GeneticChange" relationship with ALK |
| Quantitative Change |
Changes in abundance/activity/expression of a gene/protein/small molecule in a disease state |
Breast cancer has a positive "QuantitativeChange" relationship with AGK |
| State Change |
Changes in a protein's post-translational modification status or alternative splicing events |
Breast cancer has a "StateChange" relationship with estrogen receptor |
| Functional Assoc. |
Between a disease and a cellular process or another disease |
Chronic pancreatitis has a "FunctionalAssociation" relationship with pancreatic cancer |
| Chemical Reaction |
Either enzyme catalysed or spontaneous chemical reaction |
CYP3A has a "ChemicalReaction" relationship with ticagrelor |
| Molecular Synthesis |
Changes the concentration of the target |
CYP3A has a "MolSynthesis" relationship with midazolam |
| Molecular Transport |
Changes the localization of the target |
Tamoxifen has a positive "MolTransport" relationship with MAPK3 |
| Clinical Trial |
Clinical trials conducted for a drug against a disease (from CT.gov) |
Tamoxifen has a positive "Clinical Trial" relationship with breast cancer |
| Cell Expression |
Expression of proteins within or on the surface of a cell |
Hepatocyte has a "CellExpression" relationship with EGFR |